Turning Point Benefit Group’s Tarsus Pharmaceuticals TARS Stock Holding History

Turning Point Benefit Group’s Portfolio TARS Stock Details TARS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-2	Closed	-$163	–	707
2025 Q4	$163	Hold	2	–	–	﹤0.01%	777
2025 Q3	$114	Buy	+2	New	+$98	﹤0.01%	711

Other funds holding TARS

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.56% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Turning Point Benefit Group's TARS Position: Q1 2026 in Review

Turning Point Benefit Group sold out of Tarsus Pharmaceuticals (TARS) in Q1 2026, closing a stake of 2 shares — an estimated $163 sold.

Turning Point Benefit Group first reported a position in TARS in Q3 2025 and held it in 2 quarters. The position peaked at $163 in Q4 2025. 253 funds tracked by Wall St. Rank hold TARS as of Q1 2026.

Turning Point Benefit Group reported no remaining Tarsus Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Turning Point Benefit Group sold 2 Tarsus Pharmaceuticals shares in Q1 2026, an estimated $163.
Turning Point Benefit Group first reported a position in Tarsus Pharmaceuticals in Q3 2025 and held it in 2 quarters.
Turning Point Benefit Group's Tarsus Pharmaceuticals position peaked at $163 in Q4 2025.
253 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q1 2026.

Based on Turning Point Benefit Group's 13F filing for Q1 2026, filed 12 May 2026.